Corline Biomedical AB (STO:CLBIO)

Market Cap	248.58M
Revenue (ttm)	13.92M
Net Income (ttm)	-24.60M
Shares Out	24.49M
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	31.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193
Average Volume	16,541
Open	10.05
Previous Close	10.05
Day's Range	9.80 - 10.15
52-Week Range	5.98 - 13.75
Beta	0.23
RSI	52.42
Earnings Date	Aug 22, 2025

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CLBIO

Financial Performance

In 2024, Corline Biomedical AB's revenue was 17.27 million, a decrease of -51.37% compared to the previous year's 35.52 million. Losses were -23.19 million, 1182.1% more than in 2023.